

Guillaume Manson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9231070/publications.pdf>

Version: 2024-02-01

8
papers

199
citations

1478505
6
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

247
citing authors

#	ARTICLE	IF	CITATIONS
1	Interpretation of 2-[18F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors. <i>European Radiology</i> , 2022, , 1.	4.5	2
2	Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA). <i>British Journal of Haematology</i> , 2022, , .	2.5	3
3	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
4	Early ¹⁸ F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab. <i>Journal of Nuclear Medicine</i> , 2020, 61, 649-654.	5.0	39
5	Performance of CT Compared with ¹⁸ F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. <i>Radiology</i> , 2020, 295, 651-661.	7.3	30
6	Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation. <i>European Journal of Cancer</i> , 2019, 115, 47-56.	2.8	33
7	Unconventional immune-related phenomena observed using ¹⁸ F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1391-1392.	6.4	22
8	Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2856-2859.	1.4	25